Series: The T Files — Series 3: “The Injection Dark Ages"
Subtitle: 50 years of yo-yo shots, hormonal roller coasters, and the pharmacology nobody warned you about
Post: 2 of 5
Tags: testosterone enanthate, TRT history, injectable testosterone, pharmacokinetics, supratherapeutic, mood swings, standard of care
Word Count: ~1,100
In the early 1950s, pharmaceutical chemists did something clever: they attached a longer ester chain to testosterone. Seven carbon atoms instead of propionate’s three. The result was testosterone enanthate — and it was, by any reasonable measure, a dramatic improvement over what came before.
Instead of injections every two to three days, patients now needed injections every two to four weeks. The treatment burden dropped by roughly 90%. Physicians could administer doses in the clinic. Patients could actually live their lives between visits without carrying around syringes and vials.
Testosterone enanthate became the dominant form of injectable TRT for approximately fifty years. It remained the global standard of care well into the 2000s.
It was also, pharmacokinetically speaking, a hormonal rollercoaster that put patients at supratherapeutic peaks for days and subtherapeutic troughs for weeks — and the field largely accepted this as the cost of doing business.
The Numbers That Tell the Story
The approved dosing for testosterone enanthate (TE) is 50 to 400mg intramuscularly every two to four weeks. That’s a very wide range, and the variation matters enormously for what patients actually experience.
Here’s what the pharmacokinetic data show: after an IM injection, TE reaches supratherapeutic serum testosterone levels — meaning above the normal physiological range — at 36 to 48 hours post-dose. Peak serum testosterone in the 200mg dose group exceeded 1,200 ng/dL in clinical studies, which is roughly double the upper end of the normal physiological range (generally considered 300–1,000 ng/dL).
Then the decline begins.
In the 200mg every-two-weeks group, serum testosterone levels plateau near the lower therapeutic limit around day 14. For patients dosed at 300mg every three weeks or 400mg every four weeks, levels drop below the therapeutic range (below 300 ng/dL) by week three and week four, respectively.
To state this plainly: men on the most commonly used TE regimens spent portions of every dosing cycle either significantly above normal testosterone levels or significantly below them. There was a brief window in the middle where levels were actually where you wanted them.
Clinical data from a 1986 study by Nankin and Calkins on varying TE regimens (100mg weekly, 200mg every two weeks, 300mg every three weeks, and 400mg every four weeks) confirmed this pattern across all dose groups: every regimen produced a supraphysiological spike shortly after injection followed by a gradual decline toward hypogonadal territory by the end of the dosing interval.
What “Supratherapeutic” Actually Means for a Patient
The term “supratherapeutic” sounds almost positive, like you’re getting extra benefit. You are not.
When serum testosterone spikes to 1,200 ng/dL or higher in the 24–48 hours after injection, patients commonly experience: increased aggression or irritability, skin oiliness and acne, heightened libido that can be disruptive rather than welcome, insomnia, and a general sense of being wound too tight. These are the biological effects of testosterone in excess — and for two to three days after each injection, patients on standard TE dosing were running on double-normal levels.
Then, as levels declined through the second and third week, the opposite: fatigue, decreased libido, depressive episodes, brain fog, and reduced motivation. These are the symptoms of hypogonadism, returning on schedule just before the next injection.
The package insert for testosterone enanthate generics lists “fluctuation in mood/libido” as a formulation-specific adverse effect. That’s a notably understated way of describing what many patients experienced as a predictable monthly cycle of feeling briefly superhuman, then normal, then progressively symptomatic, with an injection at the nadir to start the cycle again.
Some physicians, recognizing the problem, moved patients to weekly dosing (75–100mg IM weekly) or biweekly dosing (150–200mg every two weeks) rather than the monthly or near-monthly regimens. The Endocrine Society’s Clinical Practice Guidelines eventually formally suggested these shorter intervals as alternatives. But for much of TE’s fifty-year reign as standard of care, the longer intervals dominated clinical practice because they were more convenient for the clinic — even if they were less physiological for the patient.
The Oil Vehicle Problem
Testosterone enanthate is prepared in sesame oil. This matters for a clinical reason that doesn’t get enough attention: intramuscular injection of any oil-based preparation causes local inflammation and pain at the injection site. This is not an incidental side effect — it’s a predictable consequence of pushing oil into muscle tissue.
Patients on long-term TE typically develop a personal familiarity with the particular texture of injection site soreness. The gluteal muscles are the standard target, and rotating sites helps, but there are only so many sites to rotate through when you’re getting injections for decades.
Beyond the mechanical discomfort, the oil vehicle in TE (sesame) differs from testosterone cypionate’s vehicle (cottonseed oil), which matters pharmacologically: the FDA rates TE and TC as therapeutically non-equivalent (rated AO), meaning they cannot be freely substituted without clinical consideration.
Fifty Years Is a Long Time to Accept a Problem
Perhaps the most remarkable thing about testosterone enanthate’s reign is how long the field tolerated a delivery system that was openly acknowledged to produce non-physiological hormone levels. Researchers understood the pharmacokinetic limitations of TE by the 1970s at the latest. Studies throughout the 1980s documented the peak-and-trough problem with increasing specificity.
Yet TE remained standard of care. Why?
Partly because the alternatives took time to develop. Partly because TRT as a clinical specialty had low prioritization compared to acute medicine. And partly because the prevailing attitude was that imperfect TRT was still vastly better than no TRT — which, for men with severe hypogonadism, is genuinely true.
But the limitations were recognized. By 1990, a WHO/NIH/FDA expert workshop on male contraception and hormonal therapy formally concluded that the major goal of testosterone delivery was achieving stable physiological levels — and that no available preparation was achieving this consistently. That finding, and its implications for a field that had been accepting the rollercoaster for five decades, will be the subject of our next post.
Next time: What does a hormonal rollercoaster actually look like on a graph — and what does it feel like in a human being? We dig into the pharmacokinetics of peak-and-trough injection cycling, the 1990 WHO/NIH/FDA consensus that called out the entire field, and what patients were actually experiencing that clinicians weren’t documenting.
